Introduction {#s1}
============

Hodgkin lymphoma (HL) is a lymphoproliferative malignancy originated in germinal center B-cells and is reported to account for about 10% of newly diagnosed lymphomas and 1% of all *de novo* neoplasms worldwide with an incidence of about 3 cases per 100,000 people in Western countries (Diehl et al., [@B14]). It is one of the most common tumors in young adults in economically developed countries, with one peak of incidence in the third decade of life and a second peak after 50 years of age.

Based on differences in the morphology and phenotype of the lymphoma cells and the composition of the cellular infiltrate, HL is subdivided into classical Hodgkin lymphoma (cHL) that accounts for about 95% of cases and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) that accounts for the remaining 5% of cases (Kuppers, [@B23]).

Although familial risk for HL is reported to be among the highest of all cancers (Kharazmi et al., [@B19]), not many genetic risk factors have been identified. An association between various HLA class I and class II alleles and increased risk of HL has been reported (Diepstra et al., [@B15]), while other non-HLA susceptibility loci have been detected through genome-wide association studies (Frampton et al., [@B17]; Cozen et al., [@B11]; Kushekhar et al., [@B24]). The identification of major predisposing genes is a more daunting task, however, rare germline variants in *KLDHC8B, NPAT, ACAN, KDR, DICER1*, and *POT1* gene have been reported by different groups in high-risk HL families (Salipante et al., [@B41]; Saarinen et al., [@B40]; Ristolainen et al., [@B38]; Rotunno et al., [@B39]; Bandapalli et al., [@B3]; Mcmaster et al., [@B32]).

Here we report the results of whole genome sequencing (WGS) performed in three families with documented recurrence of HL. We used our Familial Cancer Variant Prioritization Pipeline (FCVPPv2) (Kumar et al., [@B22]) as well as two gene/variant panels based on cancer predisposing genes and variants prioritized in the largest familial HL cohort study to date in order to identify possible disease-causing high-penetrance germline variants in each family (Zhang et al., [@B51]; Rotunno et al., [@B39]). Pathway and network analyses using Ingenuity Pathway Analysis software also allowed us to gain insight into the molecular mechanisms of the pathogenesis of HL. We hope that these results can be used in the development of targeted therapy and in the screening of other individuals at risk of developing HL.

Materials and Methods {#s2}
=====================

Patient Samples
---------------

Three families with documented recurrence of HL were analyzed in this study, with a total number of 16 individuals (7 affected and 9 unaffected). HL family I and family III were recruited at the University Hospital of Heidelberg, Germany, while family II was recruited at the Pomeranian Medical University, Szczecin, Poland.

The study was approved by the Ethics Committee of the University of Heidelberg and Pomeranian Medical University, Poland. Collection of blood samples and clinical information from subjects was undertaken with a written informed consent in accordance with the tenets of the Declaration of Helsinki.

Germline DNA samples used for genome sequencing were isolated from peripheral blood using QIAamp^®^ DNA Mini kit (Qiagen, Cat No. 51104) according to the manufacturer\'s instructions.

Whole Genome Sequencing, Variant Calling, Annotation and Filtering
------------------------------------------------------------------

Whole genome sequencing (WGS) of available affected and unaffected members of the three HL families was performed using Illumina-based small read sequencing. Mapping to reference human genome (assembly version Hs37d5) was performed using BWA mem (version 0.7.8) (Li and Durbin, [@B27]) and duplicates were removed using biobambam (version 0.0.148). The SAMtools suite (Li, [@B26]) was used to detect single nucleotide variants (SNVs) and Platypus (Rimmer et al., [@B37]) to detect indels. Variants were annotated using ANNOVAR, 1000 Genomes, dbSNP, and ExAC (Smigielski et al., [@B43]; Wang et al., [@B48]; The Genomes Project Consortium et al., [@B46]; Lek et al., [@B25]). Variants with a quality score \>20 and a coverage \>5×, SNVs that passed the strand bias filter (a minimum one read support from both forward and reverse strand) and indels that passed all the Platypus internal filters were evaluated further for minor allele frequencies (MAFs) with respect to the 1,000 Genomes Phase 3 and non-TCGA ExAC data. Variants with a MAF \<0.1% were deduced from these two datasets. A pairwise comparison of shared rare variants was performed to check for sample swaps and family relatedness.

Data Analysis and Variant Prioritization
----------------------------------------

### Prioritization of Coding Variants

Variant evaluation was performed using the criteria of our in-house developed variant prioritization pipeline (FCVPPv2) (Kumar et al., [@B22]). Shortly, variants with MAF \<0.1% were first filtered based on the pedigree data considering cancer patients as cases and unaffected persons as controls. The probability of an individual being a Mendelian case or true control was considered.

Variants were then ranked using the CADD tool v1.3 (Kircher et al., [@B20]). Only variants with a scaled PHRED-like CADD score \>10, i.e., variants belonging to the top 1% of probable deleterious variants in the human genome, were considered further. Genomic Evolutionary Rate Profiling (GERP) (Cooper et al., [@B10]), PhastCons (Siepel et al., [@B42]), and PhyloP (Pollard et al., [@B36]) were used to evaluate the evolutionary conservation of a particular variant. GERP scores \> 2.0, PhastCons scores \> 0.3, and PhyloP scores ≥ 3.0 were indicative of a good level of conservation and were therefore used as thresholds in the selection of potentially causative variants.

Next, all missense variants were assessed for deleteriousness using 10 tools accessed using dbNSFP (Liu et al., [@B29]), namely SIFT, PolyPhen V2-HDV, PolyPhen V2-HVAR, LRT, MutationTaster, Mutation Assessor, FATHMM, MetaSVM, MetLR, and PROVEAN. Variants predicted to be deleterious by at least 60% of these tools were analyzed further. Prediction scores for nonsense variants were attained via VarSome (Kopanos et al., [@B21]), the final verdict on pathogenicity offered by VarSome was based on the following tools: DANN, MutationTaster, FATHMM-MKL, FATHMM-XF, ALoFT, EIGEN, EIGEN PC, and PrimateAI.

Lastly, three different intolerance scores derived from NHLBI-ESP6500 (Petrovski et al., [@B35]), ExAC (Lek et al., [@B25]) and a local dataset, all of which were developed with allele frequency data, were included to evaluate the intolerance of genes to functional mutations. However, these scores were used merely to rank the variants and not as cut-offs for selection. The ExAC consortium has developed two additional scoring systems using large-scale exome sequencing data including intolerance scores (pLI) for loss-of-function variants and Z-scores for missense and synonymous variants. These were used for nonsense and missense variants, respectively.

Structural variants were analyzed using Canvas (version 1.40.0.1613) (<https://academic.oup.com/bioinformatics/article/32/15/2375/1743834>) program\'s SmallPedigree-WGS separately to detect the larger copy number variants. The joint genotyped VCF for all the samples in a family generated via Platypus was used as the b-allele input file along with the BAM files, and the rest of the parameters were kept default. Variants with "PASS" filters and present in all the cases in a family were processed further and variants overlapping common structural variants (AF \> 1%) from gnomAD (version 2.1) were marked as common and removed. The remaining rare structural variants that affects the known cancer predisposition genes were selected for the manual inspection in IGV.

### Analysis of Non-coding Variants

Variants located in the 3′ and 5′ untranslated regions (UTRs) were prioritized based on their location in regulatory regions. Putative miRNA targets at variant positions within 3′ UTRs and 1 kb downstream of transcription end sites were detected by scanning the entire dataset of the human miRNA target atlas from TargetScan 7.0 (Agarwal et al., [@B2]) using the intersect function of bedtools. Similarly, 5′ UTRs and regions 1 kb upstream of transcription start sites were scanned for putative enhancers and promoters using merged enhancer and promoter data from the FANTOM5 consortium as well as super-enhancer data from the super-enhancer archive (SEA) and dbSUPER. These regions were also scanned for transcription factor binding sites using SNPnexus (Dayem Ullah et al., [@B13]).

The regulatory nature and the possible functional effects of non-coding variants were evaluated using CADD v1.3, HaploReg V4 (Ward and Kellis, [@B49]), and RegulomeDB (Boyle et al., [@B7]), primarily based on ENCODE data (Birney et al., [@B6]). Epigenomic data and marks from 127 cell lines from the NIH Roadmap Epigenomics Mapping Consortium were accessed via CADD v1.3, which gave us information on chromatin states from ChromHmm and Segway. CADD also provided mirSVR scores to rank predicted microRNA target sites by a down-regulation score. These scores are based on a new machine learning method based on sequence and contextual features extracted from miRanda-predicted target sites (Betel et al., [@B5]). Furthermore, SNPnexus was used to access non-coding scores for each variant and to identify regulatory variants located in CpG islands.

The final selection of 3′ UTR and downstream variants was based on their CADD scores \> 10 and whether or not they had predicted miRNA target site matches. Similarly, upstream and 5′ UTR variants in enhancers, promoters, super-enhancers or transcription factor binding sites with CADD scores \>10 were short-listed.

### Presence of Candidate Variants in 565 Cancer Predisposing and Other Cancer-Related Genes

In a study on cancer predisposing genes (CPGs) in pediatric cancers, Zhang et al. compiled 565 CPGs based on review of the American College of Medical Genetics and Genomics (ACMG) and medical literature (Zhang et al., [@B51]). The categories included genes associated with autosomal dominant cancer-predisposition syndromes (60), genes associated with autosomal recessive cancer-predisposition syndromes (29), tumor-suppressor genes (58), tyrosine kinase genes (23), and other cancer genes (395). We checked a list of genes corresponding to our shortlisted coding and non-coding variants for their presence in the list of genes in the aforementioned study.

### Presence of Candidate Variants in Prioritized HL Genes From a Large WES-Based Familial HL Study

In a study by Rotunno et al. ([@B39]) 2,699 variants corresponding to 2,383 genes were identified in 17 HL discovery families after filtering and prioritization. We intersected our list of candidate genes with this list of 2,383 HL genes to identify coding and non-coding variants from our shortlist in potentially causative HL genes.

Variant Validation
------------------

Specific variants of interest mentioned throughout the text (*DICER1, HLTF, LPP, PLK3, RAD51D, RELB, SH3GL2*, and *SPTAN1*) and highlighted as bold in the tables were validated using specific primers for polymerase chain reaction amplification designed with Primer3 (<http://bioinfo.ut.ee/primer3-0.4.0/>) and Sanger sequencing on a 3,500 Dx Genetic Analyzer (Life Technologies, CA, USA), using ABI PRISM 3.1 Big Dye terminator chemistry, according to the manufacturer\'s instructions. The electrophoretic profiles were analyzed manually. Segregation analysis of the prioritized variants was performed in additional family members when DNA was available. Primer details are available on request.

Ingenuity Pathway Analysis (IPA)
--------------------------------

IPA (Qiagen; <http://www.qiagen.com/ingenuity>; analysis date 15/10/2019) was used to perform a core analysis to identify enriched canonical pathways, diseases, biological functions, and molecular networks among genes that passed the allele frequency cut-off, fulfilled family-based segregation criteria, met the CADD score cut-off and were not intergenic or intronic variants. Data were analyzed for all three families together. Top canonical pathways were identified from the IPA pathway library and ranked according to their significance to our input data. This significance was determined by *p*-values calculated using the right tailed Fisher\'s exact test.

IPA was also used to generate gene networks in which upstream regulators were connected to the input dataset genes while taking advantage of paths that involved more than one link (i.e., through intermediate regulators). These connections represent experimentally observed cause-effect relationships that relate to expression, transcription, activation, molecular modification and transport as well as binding events. The networks were ranked according to scores that were generated by considering the number of focus genes (input data) and the size of the network to approximate the relevance of the network to the original list of focus genes.

Results {#s3}
=======

Whole Genome Sequencing Results
-------------------------------

In our study, we analyzed three families with reported recurrence of Hodgkin lymphoma. Their respective pedigrees are shown in [Figure 1](#F1){ref-type="fig"}.

![Pedigrees of the three HL families analyzed in this study. **(A)** Family 1, **(B)** Family 2, and **(C)** Family 3.](fbioe-08-00179-g0001){#F1}

In family I ([Figure 1A](#F1){ref-type="fig"}), the proband (III-1) and her mother (II-2) were diagnosed with two different histological subtypes of classical Hodgkin lymphoma (cHL) at the ages of 7 and 34, respectively. The daughter was diagnosed with nodular sclerosis cHL and the mother with lymphocyte-rich cHL. The sample of the unaffected father (II-1) was also sequenced. Family II ([Figure 1B](#F1){ref-type="fig"}) is characterized by a strong recurrence of HL. Five family members were diagnosed with HL (II-3, II-4, III-3, III-4, and III-5), of which three (III-3, III-4, and III-5) underwent WGS. In addition, the family member (II-6), who was considered as an obligatory carrier of the mutation, was sequenced as were samples and four healthy family members (III-1, III-2, III-6, and III-8) and one family member diagnosed with uterine cancer (II-1) as controls. In family 3 ([Figure 1C](#F1){ref-type="fig"}), II-1 and II-2 were diagnosed with cHL, at the age of 27 and 24, respectively. Their parents (I-1, I-2) were not affected, however one of them is expected to be a carrier and analyzed accordingly.

WGS of 7 affected and 9 unaffected members from the three studied families identified a total number of 98,564, 170,550, and 113,654 variants which were reduced by pedigree-based filtering to 18,158, 465, and 26,465 in families I, II, and III, respectively.

Prioritization of Candidates According to the FCVPPv2
-----------------------------------------------------

After pedigree-based filtering, 130, 7, and 196 exonic variants were left in families I, II, and III, respectively, with a prevalence of non-synonymous and synonymous SNVs. The predominant type of substitution was the C\>T transition. Among exonic variants fulfilling pedigree-based criteria, only variants with CADD scores \>10 were taken into further consideration and prioritized according to deleteriousness, intolerance, and conservational scores, as detailed in the methods section. At the end of this process, 37 potential missense variants and 9 potential nonsense mutations were prioritized for families I---III and are shown in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}.

###### 

Top missense variants prioritized using the FCVPPv2.

  **Family ID**   **Position (Hg 19)**   **Gene**                  **Effect**     **CADD PHRED**   **Int (n/3)**   **Del (*n*/10)**   **VarSome Score**
  --------------- ---------------------- ------------------------- -------------- ---------------- --------------- ------------------ ----------------------------
  Family_1        17_48746518_C\_T       ABCC3                     p.P652L        22.6             2               7                  Uncertain significance
  Family_1        1_49052793_G\_A        AGBL4                     p.R384C        35               2               7                  Uncertain significance
  Family_1        5_139909090_A\_G       ANKHD1, ANKHD1-EIF4EBP3   p.N2187D       25.2             .               6                  Uncertain significance
  Family_1        1_160164884_T\_C       CASQ1                     p.I183T        26.5             2               10                 Likely Benign
  **Family_1**    **14_95560456_A\_C**   **DICER1**                **p.I1711M**   **24**           **3**           **7**              **Uncertain significance**
  Family_1        6_159206584_G\_A       EZR                       p.P75L         32               3               9                  Uncertain significance
  Family_1        12_8192537_G\_A        FOXJ2                     p.G37R         29.9             3               9                  Uncertain significance
  Family_1        14_88729713_C\_T       KCNK10                    p.A79T         27.1             3               6                  Uncertain significance
  Family_1        10_88705360_G\_A       MMRN2                     p.P58L         29.8             2               7                  Uncertain significance
  Family_1        5_36962227_G\_A        NIPBL                     p.R154Q        27.5             3               8                  Uncertain significance
  Family_1        2_206614449_A\_G       NRP2                      p.D596G        23.1             2               9                  Uncertain significance
  **Family_1**    **1_45268632_C\_T**    **PLK3**                  **p.T252M**    **25.3**         **3**           **6**              **Uncertain significance**
  **Family_1**    **19_45515485_T\_C**   **RELB**                  **p.I152T**    **26**           **3**           **6**              **Uncertain significance**
  Family_1        6_52372363_G\_C        TRAM2                     p.A205G        29.8             3               10                 Uncertain significance
  Family_1        22_18613830_C\_T       TUBA8                     p.A450V        24.7             3               10                 Uncertain significance
  Family_1        X_47272364_G\_A        ZNF157                    p.G298R        27.6             2               6                  Uncertain significance
  Family_2        9_116151739_G\_C       ALAD                      p.I243M        22.9             2               6                  Uncertain significance
  Family_2        9_131196759_G\_T       CERCAM                    p.A468S        24.5             2               7                  Uncertain significance
  **Family_2**    **9_131367689_C\_T**   **SPTAN1**                **p.R1327C**   **34**           **3**           **6**              **Uncertain significance**
  Family_3        9_139917418_C\_T       ABCA2                     p.G83S         26.3             2               7                  Uncertain significance
  Family_3        17_40971572_G\_C       BECN1                     p.P85R         23.4             3               6                  Uncertain significance
  Family_3        8_67968830_G\_T        COPS5                     p.P131T        23.9             3               9                  Uncertain significance
  Family_3        3_5246773_C\_T         EDEM1                     p.T160M        34               3               9                  Uncertain significance
  Family_3        6_131191103_G\_A       EPB41L2                   p.S736F        22.1             3               7                  Uncertain significance
  Family_3        8_28575243_G\_A        EXTL3                     p.R172H        23               3               6                  Likely Benign
  **Family_3**    **3_188123979_A\_T**   **LPP**                   **p.E24V**     **32**           **2**           **6**              **Uncertain significance**
  Family_3        14_74970734_C\_T       LTBP2                     p.G1493R       27.7             3               10                 Uncertain significance
  Family_3        3_196730925_C\_A       MFI2                      p.D662Y        34               3               6                  Uncertain significance
  Family_3        17_27441099_G\_A       MYO18A                    p.A843V        24.3             3               6                  Uncertain significance
  Family_3        19_14584756_A\_G       PTGER1                    p.L126P        25.9             2               6                  Uncertain significance
  Family_3        3_49138083_G\_A        QARS                      p.R301C        34               2               9                  Uncertain significance
  **Family_3**    **17_33428327_G\_A**   **RAD51D,RAD51L3-RFFL**   **p.R266C**    **27**           **3**           **8**              **Benign**
  Family_3        11_9838541_C\_T        SBF2                      p.R1275H       33               2               9                  Likely Benign
  **Family_3**    **9_17761502_A\_G**    **SH3GL2**                **p.N14S**     **26.1**         **3**           **9**              **Uncertain significance**
  Family_3        20_35467682_G\_A       SOGA1                     p.R46C         32               3               7                  Uncertain significance
  Family_3        1_43891311_G\_A        SZT2                      p.A96T         31               3               6                  Uncertain significance

*Chromosomal positions, classifications, PHRED-like CADD scores, protein changes and the number of positive intolerance (Int) and deleteriousness (Del) scores are shown for each variant. Variants of interest that were validated by Sanger sequencing in the provided family samples have been shown in bold*.

###### 

Top non-sense variants prioritized using the FCVPPv2.

  **Family ID**   **Position (Hg 19)**   **Gene**   **Exonic classification**   **Effect**     **CADD**   **Int (*n*/3)**   **VarSome score \[I\]**
  --------------- ---------------------- ---------- --------------------------- -------------- ---------- ----------------- -------------------------
  Family_1        10_88911115_AGT_A      FAM35A     Frameshift deletion         p.2_2del       25.8       2                 PM2
  **Family_1**    **3_148802664_C\_T**   **HLTF**   **Stopgain SNV**            **p.W11X**     **37**     **2**             **PP3 (4)**
  Family_1        1_177923437_CTG_C      SEC16B     Frameshift deletion         p.481_481del   36         0                 Uncertain significance
  Family_1        15_91546350_TG_T       VPS33B     Frameshift deletion         p.P321fs       36         3                 PVS1
  Family_3        7_31683260_AT_A        CCDC129    Frameshift deletion         p.D611fs       34         0                 Uncertain significance
  Family_3        1_21267855_C\_T        EIF4G3     Stopgain SNV                p.W7X          14.54      2                 PVS1, PP3 (1)
  **Family_3**    **3_188123978_G\_T**   **LPP**    **Stopgain SNV**            **p.E24X**     **40**     **2**             **PM2, PP3 (4)**
  Family_3        15_24921469_G\_A       NPAP1      Stopgain SNV                p.W152X        24.8       0                 PM2, PP3 (3)
  Family_3        1_241958547_CAG_C      WDR64      Frameshift deletion         p.836_836del   37         0                 Uncertain significance

*\[I\]VarSome Scores*.

*PM2, Pathogenic Moderat; PP3, Pathogenic Supporting (no. of scores predicting pathogenicity); Uncertain Significance: No scores could be found for the variant in question, PVS1, Pathogenic Very Strong*.

*Chromosomal positions, classifications, PHRED-like CADD scores, protein changes, the number of positive intolerance (Int) and VarSome prediction scores are included for each variant. Variants of interest that were validated by Sanger sequencing in the provided family samples have been shown in bold*.

Pedigree-based filtering also reduced the number of potentially interesting variants located in the untranslated regions to 523 for 5\'UTR variants (130 in family I, 5 in family II, and 314 in family III) and 854 for 3\'UTR variants (347 in family I, 10 in family II, and 497 in family III). These variants were further prioritized based on their CADD score \>10 and their localization in known regulatory regions ([Supplementary Table 1](#SM2){ref-type="supplementary-material"}). 5′UTR variants were analyzed by the SNPNexus tool, which allowed us to identify 4 variants located in transcription factors binding sites. In addition, the intersect function of bedtools was used to identify further 15 variants located in promoter regions and 4 located in super-enhancer regions. Among variants located in the 3′UTR region, 56 variants located in miRNA seed sequences were selected.

Analysis of structural variants resulted in identification of a large deletion in exons 9 and 10 (del5395) of Chek2 kinase gene (*CHEK2*) in family 1 that segregates with the disease.

Candidate Variants in 565 CPGs and 2383 Potentially Causative HL Genes
----------------------------------------------------------------------

Intersecting our prioritized list of candidate genes with the list of 565 CPGs, we identified 11 variants in nine genes in coding and selected non-coding regions (upstream and downstream variants, 3′ and 5′ UTRs) of the known CPGs. These include *FUBP1, SEPT6, DICER1, EZR*, and *NCOA1* from family 1 and *BCL6, RAD51D, LPP*, and *PTCH1* from family 3 ([Table 3](#T3){ref-type="table"}). *DICER1* and *PTCH1* are known in autosomal dominant cancer-predisposition syndromes, whereas the rest are categorized as being "other cancer genes."

###### 

Variants corresponding to genes present in the panel of 565 known cancer predisposition genes from a study by Zhang et al. ([@B51]).

  **Gene ID**   **HL family**   **HL gene**   **HL variant**             **Variant type**   **Variant classification**   **HGNC approved name**                                            **CADD_PHRED**   **Familial syndrome**                           **Category**
  ------------- --------------- ------------- -------------------------- ------------------ ---------------------------- ----------------------------------------------------------------- ---------------- ----------------------------------------------- --------------------
  10499         1               NCOA2         8_71316112_T\_TCCTCCTCCC   Indel              Upstream                     Nuclear receptor coactivator 2                                    15.56                                                            Other CancerGene
  8880          1               FUBP1         1_78414225_A\_G            SNVs               UTR3                         Far upstream element (FUSE) binding protein 1                     13.59                                                            Other CancerGene
  23157         1               SEPT6         X_118751062_CGTGT_C        Indel              UTR3                         Septin 6                                                          10.56                                                            Other CancerGene
  23405         1               DICER1        14_95560456_A\_C           SNVs               Non-synonymous SNV           Dicer 1, ribonuclease type III                                    24               DICER1 syndrome, Familial Multinodular Goiter   Autosomal Dominant
  7430          1               EZR           6_159206584_G\_A           SNVs               Non-synonymous SNV           Ezrin                                                             32                                                               Other CancerGene
  604           3               BCL6          3_187463568_C\_A           SNVs               Upstream; downstream         B-cell CLL/lymphoma 6                                             13                                                               Other CancerGene
  4026          3               LPP           3_188123978_G\_T           SNVs               Stopgain SNV                 LIM domain containing preferred translocation partner in lipoma   40                                                               Other CancerGene
                3               LPP           3_188123979_A\_T           SNVs               Non-synonymous SNV           LIM domain containing preferred translocation partner in lipoma   32                                                               Other CancerGene
                3               LPP           3_188608373_A\_T           SNVs               UTR3                         LIM domain containing preferred translocation partner in lipoma   10.5                                                             Other CancerGene
  5892          3               RAD51D        17_33428327_G\_A           SNVs               Non-synonymous SNV           RAD51 paralog D                                                   27                                                               Other CancerGene
  5727          3               PTCH1         9_98270531_C\_A            SNVs               Non-synonymous SNV           Patched 1                                                         20.4             Gorlin syndrome                                 Autosomal Dominant

In addition to the identification of 11 variants in CPGs, we intersected our prioritized list of genes with a list of 2,383 genes with potentially causative variants from a large WES-based familial HL study. We found 25 variants in the coding and non-coding regions in 23 of the HL genes, with 7 coming from family I and 18 from family III ([Table 4](#T4){ref-type="table"}).

###### 

Variants corresponding to genes intersecting with the list of 2,383 high-risk HL genes from a study by Rotunno et al. ([@B39]).

  **HL variants from Rotunno et al. (**[@B39]**)**   **Variant in matched gene from present study**                                                                                                                   
  -------------------------------------------------- ------------------------------------------------ ------------- --- ------------------------------------------------------- ------- ------- --------------------- ----------
  ABHD16A                                            6_31670740_A\_T                                                3   6_31671105_G\_A                                         13.23   SNVs    UTR5                  --
  C6orf62                                            6_24719009_T\_C                                  rs147402940   3   6_24705773_T\_C                                         12.31   SNVs    UTR3                  --
  CEP120                                             5_122758609_G\_T                                 rs141808885   1   5_122681069_C\_T                                        12.31   SNVs    UTR3                  --
  EDEM1                                              3_5257909_A\_G                                   rs139745426   3   3_5246773_C\_T                                          34      SNVs    Non-synonymous SNV    p.T160M
  EIF4G3                                             1_21494519_T\_C                                                3   1_21267855_C\_T                                         14.54   SNVs    stopgain SNV          p.W7X
  EPB41L2                                            6_131202023_A\_G                                               3   6_131191103_G\_A                                        22.1    SNVs    Non-synonymous SNV    p.S736F
  EXTL3                                              8_28609630_G\_A                                  rs191528081   3   8_28575243_G\_A                                         23      SNVs    Non-synonymous SNV    p.R172H
  FAM35A                                             10_88917757_A\_G                                 rs371636091   1   10_88911115_AGT_A                                       25.8    Indel   Frameshift deletion   p.2_2del
  FUK                                                16_70507153_G\_A                                               1   16_70501193_C\_T                                        10.08   SNVs    UTR3                  \-
  HLTF                                               3_148757909_A\_G                                 rs61750365    1   3_148802664_C\_T                                        37      SNVs    stopgain SNV          p.W11X
  LPP                                                3_188464149_C\_T                                               3   3_188608373_A\_T                                        10.5    SNVs    UTR3                  --
  LPP                                                3_188464149_C\_T                                               3   3_188123978_G\_T                                        40      SNVs    stopgain SNV          p.E24X
  LPP                                                                                                               3   3_188123979_A\_T                                        32      SNVs    Non-synonymous SNV    p.E24V
  LRP6                                               12_12419973_G\_T                                               3   12_12272924_AATATATATATATATATATATATATATATATATATATAT_A   12.55   Indel   UTR3                  --
  LTBP2                                              14_74983553_G\_A                                 rs145851939   3   14_74970734_C\_T                                        27.7    SNVs    Non-synonymous SNV    p.G1493R
  MAPKAP1                                            9_128199718_AT\_                                               3   9_128199770_TAA_T                                       14.3    Indel   UTR3                  --
  MARCH10                                            17_60827878_G\_A                                 rs112201730   3   17_60885673_G\_A                                        12.03   SNVs    UTR5                  --
  MYO18A                                             17_27448659_C\_T                                 rs371862120   3   17_27441099_G\_A                                        24.3    SNVs    Non-synonymous SNV    p.A843V
  NCAM1                                              11_113113556_A\_G                                              1   11_113134920_C\_A                                       11.07   SNVs    UTR3                  --
  NIPBL                                              5_36876673_G\_A                                                1   5_36962227_G\_A                                         27.5    SNVs    Non-synonymous SNV    p.R154Q
  PHC2                                               1_33820711_G\_A                                                3   1_33896663_C\_A                                         15.12   SNVs    upstream              --
  RCN1                                               11_32126524_C\_T                                               3   11_32112681_C\_T                                        10.66   SNVs    UTR5                  --
  SBF2                                               11_9985135_TAAT\_                                              3   11_9838541_C\_T                                         33      SNVs    Non-synonymous SNV    p.R1275H
  SLMAP                                              3_57914019_A\_C                                  rs191613999   1   3_57742023_C\_G                                         13.51   SNVs    UTR5                  --
  SZT2                                               1_43885320_C\_T                                                3   1_43891311_G\_A                                         31      SNVs    Non-synonymous SNV    p.A96T

*Variant details from both databases the present study and the study by Rotunno et al. ([@B39]) are shown*.

Network and Pathway Analysis With IPA
-------------------------------------

Pathway analysis of the selected variants performed with IPA showed an enrichment of mutations in genes involved in pathways essential for B-cell proliferation and activation, specifically B-cell receptor signaling, and PI3K signaling in B lymphocytes and B cell activating factor signaling ([Supplementary Table 2A](#SM3){ref-type="supplementary-material"}, [Supplementary Figures 1A,B](#SM1){ref-type="supplementary-material"}).

Similarly, the IPA network analysis generated a comprehensive picture of possible gene interactions between our candidate genes ([Supplementary Table 2B](#SM3){ref-type="supplementary-material"}). The top network is related to cancer, hematological disease and immunological disease, which is in complete coherence with the pathogenesis of HL. Many genes from the prioritized list of top candidates are shown to play a role in the top networks ([Figure 2](#F2){ref-type="fig"}).

![The top three molecular networks identified by Ingenuity Pathway Analysis: **(A)** Network 1. Cancer, hematological disease, immunological disease; **(B)** Network 2. developmental disorder, endocrine system disorders, hereditary disorder; **(C)** Network 3. RNA post-transcriptional modification, cell death and survival, cellular movement. Genes from our input-data are shown in gray, genes from our prioritized candidate list are highlighted in peach.](fbioe-08-00179-g0002){#F2}

Literature Mining, Consolidation of Results, and Selection of Candidates
------------------------------------------------------------------------

With the aim of identifying one highly penetrant dominant variant per family, we used our pipeline results and literature-based mining to determine the genes\' link to Hodgkin lymphoma or immune-related processes. For family 1, we have short-listed 5 potential candidates (*DICER1, HLTF, NOTCH3, PLK3, and RELB*). Based on segregation, confirmation and functional validation, we identified *DICER1* as a candidate HL predisposing gene by showing significant down-regulation of tumor suppressor miRNAs in *DICER1*-mutated family members (Bandapalli et al., [@B3]). The presence of *DICER1* in the list of 565 CPGs also reinforces its status as the disease-causing variant in this family.

In family 2, three exonic variants made it to the final list (*ALAD, CERCAM*, and *SPTAN1*) of which *SPTAN1* was shown to be among the genes in one of the top IPA networks (Network 3; [Figure 2C](#F2){ref-type="fig"}). No coding or non-coding variants intersected with the panel of CPGs or HL candidate genes.

Two genes stand out in family 3, namely *LPP* and *RAD51D*. Both genes were found in the list of 565 CPGs and *LPP* was additionally found in the gene list from the large cohort of HL families. Three variants in *LPP* were prioritized by the FCVPPv2 and made it to the shortlist including one stopgain variant (3_188123978_G\_T), one 3′ UTR (3_188608373_A\_T) and one non-synonymous missense variant (3_188123979_A\_T). LPP (LIM domain containing preferred translocation partner in lipoma) is a member of the zyxin family of LIM proteins that is characterized as a promoter of mesenchymal/fibroblast cell migration. LPP has been shown to be a critical inducer of tumor cell migration, invasion and metastasis by virtue of its ability to localize to adhesions and to promote invadopodia formation (Ngan et al., [@B33]). A genome-wide association study of 253 Chinese individuals with B-cell NHL also identified a new susceptibility locus between *BCL6* and *LPP* that was significantly associated with the increased risk of B-cell NHL (Tan et al., [@B45]). On the other hand, there are no reports of an association between *RAD51D* and lymphomas; however, it is a well-established susceptibility gene in Breast-Ovarian Cancer, Familial 4 and Hereditary Breast Ovarian Cancer Syndrome (Loveday et al., [@B30]; Chen et al., [@B9]). The final selection of a candidate in this family will be based on further functional studies.

Discussion {#s4}
==========

In summary, WGS data analysis of three families with reported recurrence of HL allowed us to prioritize 45 coding and 79 non-coding variants from which we subsequently selected and validated one for family I (*DICER1*), short-listed three in family II (*ALAD, CERCAM*, and *SPTAN1*) and two in family III (*RAD51* and *LPP*), to investigate further with validation and functional studies. For family I we have already functionally validated *DICER1* as the candidate predisposing gene in a previous study (Bandapalli et al., [@B3]). However, it was important to include the family in this paper, especially with regard to the integrity of the pathway and network analyses. We identified pathways related to B-cell proliferation and networks related to cancer, hematological disease, immunological disease, hereditary disorders, cell death and cell survival using IPA software, helping us to prioritize genes with functions in the pathogenesis of HL. Interestingly, several genes in our gene list were related to DNA repair (e.g., *NOTCH3, RAD51*, and *SPTAN1*).

In the current study, we also identified a deletion of exon 9 and 10 in *CHEK2* in family 1. The same deletion has been reported in several unrelated patients with breast cancer of Polish origin. In that study the deletion of exon 9 and 10 in *CHEK2* was shown to lead to a premature protein truncation at codon 381 and to evoke a 2-fold increase in the risk of prostate cancer and a 4-fold increase in the risk of familial prostate cancer (Cybulski et al., [@B12]). The detection of mRNA of abnormal length suggests that the deletion does not lead to complete transcript loss and therefore, the effect of this truncating mutation on cancer risk may differ or work in tandem with another genetic effect, may be with *DICER1* in this family but warrants further experiments. Personalized medicine is an upcoming and promising field of medicine in which medical decisions, practices, interventions, and products are tailored to the individual patient based on their predicted response or risk of disease. The scope of this field has advanced rapidly with the advent of genomics and other omics and the possibility of implicating one gene or a set of genes in the pathogenesis of a particular disease. Thus, the identification of germline predisposing genes could be of great value in the screening of individuals at risk of developing HL, as well as in the development of personalized adjuvant therapies based on the affected pathways. In this aspect, delta-aminolevulinate dehydratase (*ALAD*) from family 2 is interesting, as it is involved in the catalysis of the second step in the biosynthesis of heme and also acts as an endogenous inhibitor of the 26 S proteasome, a multi-catalytic ATP-dependent protease complex that functions as the degrading arm of the ubiquitin system, which is the major pathway for regulated degradation of proteins in all eukaryotes. Down regulation of *ALAD* is shown to be associated with poor prognosis in patients with breast cancer (Ge et al., [@B18]) whereas the existing data on non-erythroid spectrin αII (*SPTAN1*) suggest that overexpression of *SPTAN1* in tumor cells reflects neoplastic and tumor promoting activity or tumor suppressing effects by enabling DNA repair through interaction with DNA repair proteins (Ackermann and Brieger, [@B1]). *CERCAM* is known as an unfavorable prognostic marker in urothelial, renal, and ovarian cancers implying the importance of the variants in these genes (Ma et al., [@B31]). RAD51D from family III is particularly interesting since it is involved in DNA repair through homologous recombination. Therefore, it is possible that carcinomas arising in patients carrying mutations in this gene will be sensitive to chemotherapeutic agents that target this pathway, such as cisplatin and the PARP (poly (ADP-ribose) polymerase) inhibitor olaparib. This has already been demonstrated in *BRCA1/2* mutation-carrier cancer patients (Banerjee et al., [@B4]; Loveday et al., [@B30]). This approach can also be applied to target pathways affected by the mutated genes. Several candidate genes were identified by IPA pathway analysis in B cell receptor pathways, offering a valuable target for other pharmaceutical drugs. The B cell receptor (BCR) signaling pathway, when dysregulated, is a potent contributor to lympomagenesis and tumor survival (Valla et al., [@B47]). This pathway has been targeted in B-cell lymphomas and leukemias with several BCR-directed agents, such as inhibitors of Bruton\'s tyrosine kinase (BTK9), spleen tyrosine kinase (SYK) and phosphatidylinositol-3-kinase (PI3K) (Buggy and Elias, [@B8]; Dreyling et al., [@B16]; Liu and Mamorska-Dyga, [@B28]). In one study, excellent response rates could be demonstrated in certain non-Hodgkin lymphoma subtypes, however, issues related to the development of resistance to BTK inhibitors need to be addressed (Valla et al., [@B47]).

Advancements in the field of genomics have allowed WGS to become the state-of-the-art tool for the identification of novel cancer predisposing genes in Mendelian diseases. It is still a challenge to appropriately interpret the immense amount of data generated by WGS, especially with respect to non-coding variants. In our study, we have attempted to interpret a selection of non-coding variants using *in silico* and bioinformatic tools, however, the adequate analysis of intronic and intergenic variants remains a challenge. There are several reports of WGS being successfully implemented to implicate rare, high-penetrance germline variants in cancer, for example *POT1* mutations in familial melanoma and Hodgkin lymphoma (Mcmaster et al., [@B32]; Wong et al., [@B50]) and *POLE* and *POLD1* mutations in colorectal adenomas or carcinomas (Palles et al., [@B34]). In a previous study, we have used our pipeline (FCVPPv2) to prioritize novel variants in non-medullary thyroid cancer prone families (Srivastava et al., [@B44]). We have also successfully combined our pipeline with literature review and functional studies to identify *DICER1* as a candidate predisposing gene in one Hodgkin lymphoma family (Bandapalli et al., [@B3]). We aim to apply these methods in the remaining Hodgkin lymphoma families and hope that these results will facilitate personalized therapy in the studied families and contribute to the screening of other individuals at risk of developing HL.
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